Physostigmine versus naloxone in heroin-overdose

Area of Science:

• Emergency Medicine
• Clinical Pharmacology
• Toxicology

Background:

• Heroin overdose frequently causes hypoventilation and coma, necessitating emergency treatment.
• Opioid antagonists like naloxone can reverse overdose effects but may precipitate acute withdrawal syndrome in dependent individuals.

Purpose of the Study:

• To compare the efficacy and patient experience of physostigmine salicylate versus naloxone in treating heroin overdose in chronically addicted patients.
• To evaluate whether physostigmine can reverse opioid-induced respiratory depression without inducing withdrawal symptoms.

Main Methods:

• A randomized study involving two groups of 10 chronically heroin-addicted patients presenting with hypoventilation and coma.
• Patients received either intravenous naloxone (3 µg/kg BW) or intravenous physostigmine salicylate (0.04 mg/kg BW).
• Outcomes assessed included consciousness, respiratory function, and the presence or absence of opioid withdrawal symptoms.

Main Results:

• Both naloxone and physostigmine rapidly restored consciousness and adequate spontaneous respiration within 10 minutes.
• Physostigmine treatment did not induce acute opioid withdrawal symptoms; patients reported feeling well.
• Naloxone treatment resulted in significant opioid withdrawal symptoms, leading to patient distress and premature ward departure in some cases.
• The duration of physostigmine's beneficial effect was shorter compared to naloxone.

Conclusions:

• Physostigmine salicylate offers a viable alternative for treating heroin overdose in opioid-dependent individuals, avoiding the distressing withdrawal syndrome associated with naloxone.
• Managing heroin overdose can be achieved without compromising the patient's immediate well-being by preventing acute opioid withdrawal.